메인메뉴 바로가기 본문내용 바로가기

의약품 부작용신고 및 피해구제 상담 : 1644-6223 / 14-3330

첨단바이오 포커스

국민의 안전과 건강을 지키는 한국의약품안전관리원

홈 > 알림마당 > 뉴스레터 > 첨단바이오 포커스

인쇄
게시글 보기
제목 첨단바이오 포커스 제8호
등록자 hyj0117 등록일 2021-08-06 조회수 2361





















Reference

1. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45541&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=2

2. 식품의약품안전처 홈페이지 Available from:

https://www.mfds.go.kr/brd/m_1060/view.do?seq=14860&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=2

3. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_1060/view.do?seq=14849&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1

4. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45451&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=3

5. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq=45434&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=2

6. “MIDD Immunogenicity Workshop” US FDA Accessed May 28, 2021 Available from: https://www.fda.gov/media/147871/download

7. “Important Patient and Consumer Information About Regenerative Medicine Therapies” US FDA Accessed June 3, 2021

Available from: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies

8. “Regulatory Education for Industry (REdI) Annual Conference 2021” US FDA Accessed June 3, 2021 

Available from: https://www.fda.gov/drugs/regulatory-education-industry-redi-annual-conference-2021-07192021-07232021

9. “SUPPLEMENT APPROVAL ” US FDA Accessed June 11, 2021 Available from: https://www.fda.gov/media/150087/download

10. “FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns“ Accessed June 15, 2021

Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-stratagraft-treatment-adults-thermal-burns

11. “BLA APPROVAL” US FDA Accessed June 15, 2021 Available from: https://www.fda.gov/media/150131/download

12. “Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products; Guidance for Industry” US FDA Accessed June 21, 2021

Available from: https://www.fda.gov/media/109615/download

13. “SUPPLEMENT APPROVAL” US FDA Accessed June 30, 2021 Available from: https://www.fda.gov/media/150463/download

14. “FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee” US FDA Accessed Dec 13, 2016

Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-autologous-cellularized-scaffold-repair-cartilage-defects-knee

15. “Transcripts for the Patient Engagement & Regenerative Medicine An FDA Workshop for Patient Advocate” US FDA Accessed June 30, 2021

Available from: https://www.fda.gov/media/150446/download

16. “Slides for the Patient Engagement & Regenerative Medicine: An FDA CBER Workshop for Patient Advocates” US FDA Accessed June 30, 2021

Available from: https://www.fda.gov/media/150445/download

17. “ Committee for Advanced Therapies (CAT): work-plan-2021-Jun” EMA. Accessed Jun. 16, 2021 Available from:

https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-16-18-june-2021-meeting_en.pdf

18. Abecma” EMA. Accessed Jun. 25, 2021 Available from: 

https://www.ema.europa.eu/en/news/first-cell-based-gene-therapy-treat-adult-patients-multiple-myeloma

19. “Orphan designations-eu304194EMA. Accessed May. 31, 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu304194

20. “Orphan designations-eu3161740EMA. Accessed Jun. 11, 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161740

21. “Orphan designations-eu3202297EMA. Accessed Jun. 24, 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202297

22. “Orphan designations-eu3151434EMA. Accessed Jun. 25, 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151434

23. “Orphan designations-eu3151578EMA. Accessed Jun. 24, 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3151578

24. “Orphan designations-eu3202312” EMA. Accessed Jun. 24, 2021  

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202312

25. “Orphan designations-eu3202297EMA. Accessed Jun. 23, 2021 

Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202297

26. “Dacogen” EMA. Accessed Jun. 04, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen

27. “Takara Bio grants BioNTech a commercial patents license of CAR T-cell Therapy drug” Biospectrum. Accessed June. 25, 2021

https://www.biospectrumasia.com/news/50/18447/takara-bio-grants-biontech-a-commercial-patents-license-of-car-t-cell-therapy-drug.html

28. “Japan's Fujifilm invests ¥90 B to increase capacity for biologics” Biospectrum. Accessed July. 6, 2021

https://www.biospectrumasia.com/news/50/18513/japans-fujifilm-invests-90-b-to-increase-capacity-for-biologics.html

29. “RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies” Biospace. Accessed July. 7, 2021

https://www.biospace.com/article/releases/replicel-applies-for-manufacturing-approval-for-its-collagen-and-tissue-regeneration-cell-therapies/

30. 보건복지부 보도자료Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=350418&page=1

31. Iglesias-Lopez C., et al. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Cytotherapy. 2021 Mar;23(3):261-274.

32. ARM (Alliance for Regenerative Medicine), 2020: Growth & Resilience in Regenerative Medicine Annual Report, 2021. 3.

Available from: https://alliancerm.org/sector-report/2020-annual-report/

33. 한국바이오협회, 글로벌 첨단바이오의약품(재생의료) 산업 동향 보고서

Available from: https://www.koreabio.org/board/board.php?bo_table=report&key_type=b_subject&key_word=%EA%B8%80%EB%A1%9C%EB%B2%8C&idx=37

34. 생명공학정책연구센터, BioINwatch: 유전자, 세포 및 RNA 치료제 개발 활기

Available from: https://www.bioin.or.kr/board.do?num=307290&cmd=view&bid=issue&cPage=1&cate1=all&cate2=all2&s_key=title&s_str=%20RN&sdate=&edate=

35. 생명공학정책연구센터, BioINregulation: 미국 21세기 치유법 (21st Century Cures)의 바이오 규제혁신

Available from: https://www.bioin.or.kr/regulationView.do?num=307084&cmd=view&bid=regulation&cPage=1

36"Regenerative Medicine Advanced Therapy Designation" US FDA. Last modifed July 6, 2021 Available from:

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation

37. “PRIME: priority medicines” EU EMA. Accessed Jul 12, 2021

Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines

38. “Strategy of SAKIGAKE by MHLW” Japan PMDA. Accessed Jul 12, 2021

Available from: https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html

39. “Cumulative CBER Regenerative Medicine Advanced Therapy (RMAT) Designation Requests Received by Fiscal Year” US FDA. Last modifed June 30, 2021

Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/cumulative-cber-regenerative-medicine-advanced-therapy-rmat-designation-requests-received-fiscal

40. “Annual report 2020 published” EU EMA. Updated June 14, 2021

Available from: https://www.ema.europa.eu/en/documents/annual-report/2020-annual-report-european-medicines-agency_en.pdf

41. 미국약물정보학회 Sakigake System: From Pilot to Permanent Summary and Impact of Pharmaceutical & Medical Device Act Amendments in JapanAkiko Ikeda Janssen Pharmaceutical K.K.

Available from: https://globalforum.diaglobal.org/issue/december-2020/sakigake-system-from-pilot-to-permanent-summary-and-impact-of-pharmaceutical-medical-device-act-amendments-in-japan/

42. Qui T., Hanna E., and Toumi M. PB149 The expedited regulatory programs for regenerative medicines in the US, EU and Japan. Value in Health 2019 Vol. 22, Supplement S426.

43. 채수미, 박은자, 주민희, 구현민, 유원곤, 박실비아* 희귀의약품 제도의 국가별 비교 연구. 보건사회연구 2013. 33(2), 525-548

44. 한국보건산업진흥원, 국내외 희귀의약품 (Orphan Drug) 시장 및 연구개발 현황 분석

Available from: https://www.khidi.or.kr/board/view?&linkId=48774874&menuId=MENU01783&link=%26linkId%3D48774874%26menuId%3DMENU01783

45. 생명공학정책연구센터, BioINwatch: 희귀의약품 글로벌 시장 현황 및 전망

Available from: https://www.bioin.or.kr/board.do?num=259072&cmd=view&bid=issue&cPage=1&cate1=all&cate2=all2

46. 식품의약품안전평가원, [Apec 규제조화센터] 유럽의약품청 의약품허가제도

Available from: http://www.nifds.go.kr/brd/m_95/view.do?seq=30960&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1

47. “Incentives and Regulatory consideration in orphan drug,medical device developmentJapan PMDA. Accessed Jul 12, 2021

Available from: https://www.pmda.go.jp/files/000205953.pdf

48. “2017 Summary Basis for Regulatory Action YESCARTA” US FDA. Last updated Oct 18, 2017

Available from: https://www.fda.gov/media/108788/download

49. “2017 Summary Basis for Regulatory Action KYMRIAH” US FDA. Last updated Oct 30, 2017

Available from: https://www.fda.gov/media/107962/download

50. “Kymriah : EPAR - Public assessment report” EU EMA. Last updated Sep 19 2018

Available from: https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf

51. “Yescarta : EPAR - Public assessment report” EU EMA. Last updated Sep 10 2018

Available from: https://www.ema.europa.eu/en/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf

52. “Health technology assessment bodies” EU EMA. Accessed July 12, 2021

Available from: https://www.ema.europa.eu/en/partners-networks/health-technology-assessment-bodies

53. Seimetz D., Heller K., Richter J. Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs? Cell Med. 2019 Jan 22;11:2155179018822781.

54. “Draft toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME marketing authorisation applications” EU EMA. Updated Feb 2, 2021

Available from:

https://www.ema.europa.eu/en/documents/scientific-guideline/draft-toolbox-guidance-scientific-elements-regulatory-tools-support-quality-data-packages-prime_en.pdf

55. “Recommendations on medication errors” EU EMA. Accessed July 12, 2021

Available from:

https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medication-errors/recommendations-medication-errors

56. “2018 Assessment report KYMRIAH” EU EMA. Updated June 28 2018

Available from: https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf

57. 식품의약품안전평가원, “2018년도 의약품위해성관리계획 (RMP) 교육 워크숍 발표자료

Available from: https://www.nifds.go.kr/brd/m_13/view.do?seq=9640&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=3

58. Seoane-Vazquez E., Shukla V., Rodriguez-Monguio R Innovation and competition in advanced therapy medicinal products. EMBO Mol Med. 2019 Mar;11(3):e9992.

59. 생명공학정책연구센터, BioINdustry: 글로벌 희귀의약품 시장 및 전망

Available from: https://www.bioin.or.kr/board.do?num=301797&cmd=view&bid=watch

60. ”PMDA, Regenerative Medical Product, List of Approved Product“ Japan PMDA. Updated March, 2021

Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0002.html

61. Tanaka M., et al. Achievements and challenges of the Sakigake designation system in Japan. Br J Clin Pharmacol. 2021. Mar10; doi: 10.1111/bcp.14807.

 

첨부파일
첨단바이오포커스 제8호 (21년 8월).pdf [16161676 byte]